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E-cadherin (epithelial-cadherin), encoded by theCDH1 gene, is a transmembrane glycoprotein playing a crucial role inmaintaining
cell-cell adhesion. E-cadherin has been reported to be a tumor suppressor and to be down regulated in gastric cancer. Besides genetic
mutations in CDH1 gene to induce hereditary diffuse gastric cancer (HDGC), epigenetic factors such as DNA hypermethylation
also contribute to the reduction of E-cadherin in gastric carcinogenesis. In addition, expression of E-cadherin could be mediated
by infectious agents such as H. pylori (Helicobacter pylori). As E-cadherin is vitally involved in signaling pathways modulating
cell proliferation, survival, invasion, and migration, dysregulation of E-cadherin leads to dysfunction of gastric epithelial cells
and contributes to gastric cancer development. Moreover, changes in its expression could reflect pathological conditions of
gastric mucosa, making its role in gastric cancer complicated. In this review, we summarize the functions of E-cadherin and the
signaling pathways it regulates. We aim to provide comprehensive perspectives in the molecular mechanism of E-cadherin and
its involvement in gastric cancer initiation and progression. We also focus on its applications for early diagnosis, prognosis, and
therapy in gastric cancer in order to open new avenues in this field.
1. Introduction
Gastric cancer (GC) is the third leading cause of cancer-
associated death worldwide [1]. More importantly, it is
predicted that deaths from gastric cancer will rise from the
15th to the 10th cause of mortality from all causes globally
by 2030 [2]. This underlies the emergency of breakthroughs
in molecular mechanism of gastric cancer development to
attenuate its harm. There are two main histological types
of GC according to the World Health Organization (WHO)
and the Laure´n classifications, diffuse gastric cancer and
intestinal gastric cancer, with distinct clinicopathological
features [3]. Intestinal gastric cancer is more associated with
environmental factors such as infection ofH. pylori, high salty
diet, smoking, and obesity [4, 5], while diffuse gastric cancer
is composed by noncohesive cells and is more commonly
observed in younger patients, with an obvious hereditary
form. It has been reported that around 10% of the gastric can-
cer cases are familial clustering [6]. And the cases are defined
to be hereditary diffuse gastric cancer (HDGC) by meeting
the following criteria proposed by the International Gastric
Cancer Linkage Consortium (IGCLC): (1) two or more
documented cases of diffuse gastric cancer in first/second
degree relatives, with at least one diagnosed before the age
of 50 or (2) three or more cases of documented diffuse gastric
cancer in first/second degree relatives, independently of age
[7]. Interestingly, it has been reported that around 30% of the
HDGC family harbor germline mutation of CDH1 gene [8].
The CDH1 gene locates in the human chromosome
16q22.1 and comprises 16 exons transcribed into a 4.5 Kb
mRNA and encodes for E-cadherin [9]. E-cadherin is a
calcium-dependent cell-cell adhesionmolecule playing a cru-
cial role in establishing epithelial architecture and maintain-
ing cell polarity and differentiation [10, 11]. Germline muta-
tions ofCDH1 gene predispose an individual to diffuse gastric
cancer, and subsequent inactivation of the second allele of
E-cadherin triggered by methylation, mutation, or loss of
heterozygosity (LOH) leads to HDGC [12, 13]. Moreover, it
has been revealed that cancer cells can disseminate to distant
organs and dramatic alterations exist between cancer cells
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and extracellular-matrix components [14]. This leads to the
attention that alterations in cell-cell adhesion and cell-matrix
adhesion render tumor progression. Therefore, E-cadherin
is pivotal in maintaining the epithelial architecture and cell
polarity, while dysregulation of E-cadherin contributes to
tumor invasion and progression [15], mainly diffuse gastric
carcinoma in this review.
In addition to its role in cell-cell adhesion, E-cadherin
and the cadherin-catenin complex could modulate vari-
ous signaling pathways in epithelial cells, including Wnt
signaling, Rho GTPases, and NF-𝜅B pathway. Therefore,
dysregulation of E-cadherin promotes dysfunctions of these
signaling pathways and influences cell polarity, cell survival,
invasion, and migration in gastric carcinogenesis [16].
In this review, we summarize the function of E-cadherin
and its associated signaling pathways, as well as the dys-
function of E-cadherin in gastric carcinogenesis, with an
emphasis on diffuse gastric cancer. We also focus on the
clinical applications of E-cadherin for diagnosis, prognosis,
and therapy for gastric cancer.
2. Functions and Signaling Pathways
of E-Cadherin
2.1. Structure and Functions of E-Cadherin. The E-cadherin
glycoprotein is composed of three major structural domains:
a single transmembrane domain, connecting with a cyto-
plasmic domain, and an extracellular domain comprising
five tandemly repeated domains called EC1–EC5, which are
exclusive to cadherins [17]. The extracellular domain of E-
cadherin is essential for cell-cell adhesion, as well as for the
correct folding and homo/heterodimerisation of the proteins.
The cytoplasmic domain of E-cadherin interacts with the
catenins (𝛼-, 𝛽-, 𝛾- and p120 catenin) anchored to the
actin cytoskeleton, establishing cadherin-catenin complex
[18]. E-cadherin predominantly expressed at the membrane
of epithelial cells, where it exerts cell-cell adhesion and
suppresses invasion [10, 19]. Conformation of E-cadherin
is only stable upon Ca2+ binding to its highly conserved,
negatively charged extracellular motifs [20]. Its stabilization
at the cell membrane and accurate function occur by associa-
tion to cytoplasmic p120-catenin [21] (Figure 1). The stability
of the cadherin-catenin complex, and its linkage to actin
filaments, forms the core of the Adherens Junction (AJ),
which is vital to inhibit individual epithelial cell motility and
to provide homeostatic tissue architecture [22, 23]. Being
a principal component of AJs, E-cadherin is essential for
cell-cell contact of gastric epithelium. Hence, decrease of E-
cadherin obviously contributes to dissemination of gastric
cancer cell and further tumor progression.
2.2. Signaling Pathways Regulated by E-Cadherin. In addition
to its role in cell-cell adhesion, E-cadherin is involved
in a number of signaling pathways in carcinogenesis. As
downregulation of E-cadherin in epithelial cells results in a
reduced cell polarity and increased migratory and invasive-
growth properties, loss of E-cadherin stimulates active signals
that initiate epithelial mesenchymal transition (EMT) [24,
25]. Based on the various interaction partners of E-cadherin
and the connection of the cytoplasmic cell-adhesion complex
(CCC) to the actin cytoskeleton, a number of signaling
pathways including Wnt signaling, Rho GTPases, and EGFR
are thought to have an active part in the EMT process
[22]. For the Wnt/𝛽-catenin pathway, nonsequestered, free
𝛽-catenins may accumulate in the cytoplasm attributed to
nonfunctional APC (adenomatous polyposis coli) or GSK-
3𝛽 (glycogen synthase kinase 3𝛽) [26]. High level of 𝛽-
catenins in the cytoplasm subsequently translocates into the
nucleus, binds to members of the TCF/LEF1 (Transcription
Factor/Lymphoid enhancer-binding factor 1) family, and
activates the expression ofWnt target genes, including CD44,
c-MYC, cyclin D1, and MMP7 [27]. Activation of these
genes contributes to increased cell proliferation and tumor
progression.Hence, it is supposed that E-cadherin expression
can suppress Wnt/𝛽-catenin signaling by sequestering 𝛽-
catenin at sites of cell-cell contact. Evidence suggests that
the mere presence of the E-cadherin cytoplasmic domain,
rather than E-cadherin adhesive properties, is required to
inhibit Wnt/𝛽-catenin dependent gene expression [28]. In
various cellular systems, it has been demonstrated that
sequestration of 𝛽-catenin by E-cadherin can compete with
the 𝛽-catenin/TCF-mediated transcriptional activity of the
canonical Wnt signaling pathway [22].
Besides the Wnt signaling, another pathway frequently
overexpressed in gastric cancer involves Rho GTPases, with
Rho A, Rac1, and Cdc42 extensively studied [29, 30]. These
molecules are known to play a critical role in cytoskeleton
organization and cell motility [31]. It has been revealed that
increasedRhoAactivity, which led to highermigration capac-
ity, was induced by HDGC-associated E-cadherin missense
mutations in the extracellular domain [32]. In addition, acti-
vation of RhoA through an E-cadherin dependent pathway
involves the role of EGFR (epidermal growth factor receptor)
[33]. Mutations at the E-cadherin extracellular domain may
impair the interaction of E-cadherin and EGFR, lead to
activation of EGFR, and further enhance cellmotility through
activation of RhoA [34]. Moreover, loss of E-cadherin and
release of p120-catenin activate the Rac1-MAPK (mitogen-
activated protein kinase) signaling pathway and promote
transformed cell growth [35]. In summary, inactivation of
E-cadherin leads to dysregulation of its associated signaling
pathways and contributes to the EMT process and tumor
progression.
Interestingly, the E-cadherin/catenin complex appears to
possess the ability to downmodulate NF-𝜅B activity [36].
Importantly, NF-𝜅B regulates the phenotype of epithelial cells
during inflammation, which has been shown instrumental
to inflammation associated carcinogenesis, such as H. pylori
infection in gastric cancer [37]. In mammals, the canonical
NF-𝜅B activation pathway mainly applies to p65:p50 dimers,
which are sequestered in a quiescent state in the cytoplasm
by I𝜅B family members under steady state. On stimulation
by a broad range of inflammatory mediators, including
cytokines and microbial or endogenous danger-associated
molecules, p65:p50 is released after I𝜅B phosphorylation
by the IKK complex and subsequent degradation of this
inhibitor. Finally, the heterodimer is translocated to the
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Figure 1: Schematic structure of E-cadherin and its binding to catenin proteins. The E-cadherin glycoprotein is composed of three major
structural domains: an intracellular domain, a single transmembrane domain, and an extracellular domain comprising five tandemly repeated
domains EC1–EC5. The intracellular domain of E-cadherin interacts with the catenins including 𝛼-, 𝛽-, 𝛾-, and p120 catenin. The catenin
anchors to the actin cytoskeleton, establishing cadherin-catenin complex. Conformation of E-cadherin is only stable upon Ca2+ binding to
its extracellular motifs. Its stabilization at the cell membrane and accurate function occur by association to cytoplasmic p120-catenin.
nucleus and activates the transcription of various target genes
including Bcl-2, IL-6, and TNF [38]. The activation of these
targets increases cell survival; reduces cell apoptosis; and
contributes to inflammation associated cancer development.
In a cellular system, it was shown that a forced overexpression
of E-cadherin reduces NF-𝜅B activation, whereas loss of E-
cadherin results in an increased activity of NF-𝜅B transcrip-
tion factor [39]. In addition, NF-𝜅B suppression might result
from a physical association with the E-cadherin/catenin
complex [40]. Hence, the activation of NF-𝜅B through
downregulation of E-cadherin provides convenience for the
H. pylori infection associated gastric cancer development.
To summarize the above, dysregulation of E-cadherin
leads to dysfunctions of E-cadherin-mediated signaling path-
ways, which alters cell polarity, increases cell survival, and
promotes EMT process as well as cell invasion and migration
[41]. These effects induce cancer initiation and progression,
including gastric cancer (Figure 2).
3. Genetic Mutations and Variants of
E-Cadherin in Diffuse Gastric Cancer
E-cadherin acts as a tumor suppressor and downregulation of
E-cadherin is observed in various cancers [42].Geneticmuta-
tion is one major mechanism for silencing tumor suppressor
genes. Somatic mutations of CDH1 have been identified in
sporadic diffuse gastric cancer [43, 44], colorectal cancer
[45], lobular breast cancer [46, 47], and ovarian cancer
[48]. However, the report of familial gastric cancer without
elevated rate of cancers in other organs suggested that
alterations in the germline induced this inherited cancer
[7, 49]. Germline mutation of CDH1 was first reported
in DNA extracted from lymphocytes of two patients with
gastric cancer and four obligate carriers in New Zealand.The
analysis of exon 2 to exon 16 of CDH1 gene using the single
stranded conformational polymorphism (SSCP) technique
revealed a band shift in exon 7. Direct sequencing identified
a G > T transversion in this exon. This mutation was not
observed in 150 unrelated chromosomes [50]. Since then,
genetic and germline mutations in CDH1 gene have been
analyzed widely in other populations with a family history
of diffuse gastric cancer or patients with early onset diffuse
gastric cancer (EODGC) (Table 1). These mutations lead to
truncated proteins of E-cadherin, abnormal alterations of the
E-cadherin’s calciumbinding sites, or increased its proteolytic
degradation, which inactivate its functions. Inactivation of E-
cadherin decreases cell-cell adhesion and induces aberrant
alternations of E-cadherin-associated signaling pathways
involving in cell proliferation, EMT process, and inflamma-
tion, and so forth. These aberrant changes trigger gastric
cancer development.
4. Epigenetic Alterations and
H. pylori Infection in Regulation of
E-Cadherin Expression
Other than genetic mutations in CDH1 gene to induce down-
regulation of E-cadherin, epigenetic factors alsomodulate the
expression of E-cadherin. DNAmethylation is amajor type of
epigenetic alterations and promoter hypermethylation exerts
such modulation [55]. Germline mutations of CDH1 gene
predispose an individual to HDGC, and promoter hyper-
methylation frequently acts as the second hit to completely
silence the gene. In sporadic diffuse gastric cancer, promoter
hypermethylation of CDH1 is more prevalent than mutation
of the gene [56]. Moreover, it has been well studied that
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Figure 2: E-cadherin regulated signaling pathways involved in gastric cancer, including Wnt/𝛽-catenin pathway, Rho GTPases, NF-𝜅B
pathway, EGFR, and Rac-MAPK signaling. Activation of these pathways leads to increase in cell proliferation, decrease in cell apoptosis,
cell migration, and inflammation associated gastric cancer development.
Table 1: Genetic mutations of E-cadherin (CDH1) in diffuse gastric cancer in populations.
Population Analytical methods Mutations/variants References
New Zealand SSCP and sequencing 1008G>T in exon 7 [50]
Portuguese PCR-SSCP and sequencing 1901C>T in exon 12 [51]
Chinese PCR-DHPLC and sequencing 2253C>T in exon 14 [52]
Italian SSCP, PCR and sequencing 163+37235G>A variant in intron 2 [53]
Korean PCR, sequencing, and MLPA 1003C>T in exon 7 [54]
SSCP: single stranded conformational polymorphism; PCR: polymerase chain reaction; DHPLC: denaturing high-performance liquid chromatography;MLPA:
multiplex ligation-dependent probe amplification.
H. pylori infection is the strongest risk factor for gastric
cancer development [57, 58]. Importantly,H. pylori infection
modulates the promoter methylation status of abundant
tumor suppressor genes in initiation and progression of
gastric cancer, including CDH1 (E-cadherin) [59]. CDH1
methylation seems to be an early event in H. pylori gastritis.
It has been reported that H. pylori infection is associated
with CDH1 methylation in chronic gastritis patients [60].
Downregulation of E-cadherin by methylation was detected
in precancerous lesions of gastric cancer, indicating that E-
cadherin plays an important role in gastric cancer initiation
[61]. More importantly, H. pylori is an independent risk
factor associated with methylation of E-cadherin in nonle-
sion gastric mucosa from patients with dyspepsia [62]. The
above evidence shows that DNA methylation is critical in
modulating the expression of E-cadherin and such process
can be regulated by H. pylori infection at the early stage of
gastric cancer development. This provides potential clinical
applications for diagnosis, prognosis, and therapeutic targets
in gastric cancer, which will be discussed in the following
part.
5. E-Cadherin in Clinical Applications for
Gastric Cancer
As E-cadherin plays a significant role in cell connection
and its associated signaling pathways modulates epithelial
cell fates and inflammation in gastric mucosa, inactivation
of E-cadherin is critical in gastric cancer initiation and
progression.Hence, evaluation of expression of E-cadherin or
alterations in its encoded CDH1 gene may provide promising
applications for diagnosis, prognosis, or therapeutic targets
for gastric cancer. The expression of E-cadherin is regulated
by numerous factors including genetic mutations, DNA
methylation, and H. pylori infection. It is assumed that
detection of alterations in E-cadherin or its expression could
reflect pathological conditions of stomach.
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5.1. Soluble E-Cadherin as a Biomarker for Gastric Cancer.
The extracellular domain of E-cadherin can be proteolytic
cleaved byADAMs (a disintegrinmetalloproteinases),MMPs
(matrix metalloproteinases), and KLK7 (kallikrein-related
peptidase) under certain pathological stimulus such as H.
pylori infection in the epithelial cells of stomach [63].Thepro-
teolytic cleavage of E-cadherin generates an 80 kDa fragment
which is released from the cell surface into circulation. This
fragment of E-cadherin is termed as soluble E-cadherin [64].
Detection of soluble E-cadherin by ELISA (enzyme-linked
immunosorbent assay) in circulation could indicate the status
of gastric cancer. Two decades ago, it was first reported that
soluble E-cadherin was elevated in serum of patients with
gastric cancer compared with nontumor controls (𝑁 = 22)
[65]. It was later confirmed in a larger sample size of gastric
cancer patients (𝑁 = 81) [66]. This evidence indicates
that soluble E-cadherin may serve as a prospective tumor
marker that accurately reflects the progressive regeneration
of E-cadherin at tumor sites. Furthermore, analysis of soluble
E-cadherin in serum and cancer tissue provides hints for
elucidating the mechanism of decrease of E-cadherin in
cancer cells [67]. Moreover, high concentration of soluble
E-cadherin in the serum of patients with gastric cancer
predicts tumor T4 depth invasion and poor survival [68,
69], suggesting that E-cadherin could be applied as a valid
prognosticmarker for gastric cancer. It has also been revealed
that high levels of soluble E-cadherin in serum 3 to 6 months
after curative surgery could predict recurrence of gastric
carcinoma [70]. The evidence mentioned above indicates
that soluble E-cadherin could serve as a potential biomarker
in diagnosis, prognosis, and tumor recurrence of gastric
cancer.
5.2. Genetic Mutations of E-Cadherin (CDH1) for Clini-
cal Management of Diffuse Gastric Cancer. As germ line
mutation in E-cadherin (CDH1) gene was strongly involved
in hereditary diffuse gastric cancer (HDGC), it was first
proposed guidelines for clinical management of patients with
familial diffuse gastric cancer in 1999. Later, the guidelines
were updated in 2010 [7, 8]. These guidelines suggested
that genetic counseling was essential for the evaluation and
management of HDGC. Individuals with familial diffuse
gastric cancer should take CDH1 genetic screening and
MLPA (multiplex ligation-dependent probe amplification) at
a suggested age [71]. Individuals without CDH1 mutation
should take clinical surveillance by EGD (oesophagogas-
troduodenoscopy), while the ones with CDH1 high risk
missense mutations or truncating mutations was strongly
recommended to take prophylactic gastrectomy and under
close follow-up [8, 49]. The purpose of the guidelines is
to establish a system to collect and collate data centrally,
to combine the research process and clinical practice for
a better patient management for the families affected by
HDGC.
E-cadherin is encoded by the CDH1 gene. CDH1 gene
is transcribed into a 4.5 Kb pre-mRNA. This pre-mRNA
is processed to introns removal and exons connection,
eventually generating distinct mRNA and protein of E-
cadherin. The process of pre-mRNA to mature mRNA is
called splicing. Splicing is regulated by cis-elements and
trans-elements [72]. Abnormal alterations in these elements
may lead to aberrant splice variants or abnormal expression,
inducing dysregulation of maturation of E-cadherin. Abnor-
mal maturation of E-cadherin leads to downregulation of E-
cadherin and contributes to human hereditary diffuse gastric
cancer (HDGC). Although still at the preliminary phase, it
has been pointed out that targeting alternative pre-mRNA
splicing such as the aberrant splice variants or their resulting
products are potential therapeutic targets for HDGC [72].
It was reported that a germ-line splice site mutation (1135 ∧
IVS8 + 5del8ins5) of CDH1 was identified in four members
(father and three daughters) of a family with HDGC [73].
Besides gastric cancer [74, 75], splice site mutations of CDH1
were also revealed in colorectal cancer and breast cancer
[76, 77]. If the products generated from alternative pre-
mRNA splicing of CDH1 are identified, it will be possible to
treat cancer patients more selectively.Through regulating the
altered splice variants of the target gene rather than the whole
target gene of an individual patient, personalized therapies
are possible. However, one of the most important issues to be
resolved is the development of a drug delivery system suitable
for the therapeutics [78, 79].
5.3. H. pylori Infection and DNA Hypermethylation of E-
Cadherin (CDH1) for Clinical Application for Gastric Cancer.
H. pylori infection is involved in promoter hypermethylation
of genes associated with the initiation and progression of
gastric carcinogenesis [59]. Methylation of CDH1 has been
reported to be regulated by H. pylori infection in chronic
gastritis and intestinal metaplasia patients, indicating that E-
cadherin plays an important role in gastric cancer initiation
[60, 62]. Importantly, eradication of H. pylori infection is
able to reverse the hypermethylation status of CDH1, thus
delaying or reversingH. pylori induced gastric carcinogenesis
[60].
In addition to eradication of H. pylori infection, chronic
aspirin use was indicated to be associated with a significantly
lower methylation rates of CDH1 gene (nonuser versus user
36.1% versus 10.8%, 𝑃 = 0.005) in the gastric mucosa
of H. pylori infection positive subjects [80]. Moreover,
chronic NSAID (nonsteroidal anti-inflammatory drug) use
was revealed to be inversely correlated with CIHM (CpG
island hyper methylation) as an independent factor (OR =
0.18, 95% CI = 0.06–0.48) [81]. This suggests that NSAID
can suppress CIHM of E-cadherin in the human gastric
mucosa. Hence, chronic aspirin use or NSAID use may
have suppressive role against methylation-related gastric
carcinogenesis.
On the other hand, epigenetic alterations are reversible,
drugs or chemical compounds with demethylating activity,
such as 5-aza-2󸀠-deoxycytidine (5-aza-dC), could be applied
for patients with methylation of multiple tumor suppres-
sor genes [82, 83]. Such therapy could also reverse the
methylation status of CDH1 and lead to reactivate the E-
cadherin. Considering the adverse effects of 5-aza-dC, such
as nonspecific demethylating and inducing genome wide
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hypomethylation, DNMT- (DNA methylation transferase-)
targeted strategy has been proposed and may prove to be
more effective than demethylating agents [84, 85].
6. Conclusions and Future Perspectives
Although alterations in E-cadherin and its expression may
serve as promising biomarkers or therapeutic targets in
gastric cancer, it should be aware of the potential pitfalls
before applying for clinic. For example, it was reported
that concentration of soluble E-cadherin did not elevate
significantly in gastric cancer patients compared with healthy
controls of a study in UK (𝑁 = 45) [86]. This might
be attributed to the influence of age as it seemed that the
concentration of soluble E-cadherin and other adhesion
molecules increased as aging [87, 88]. Hence, comparison of
serum levels of soluble E-cadherin should be considered in
age-matched populations [89].
Moreover, a study of genetic analysis of CDH1 gene in a
Polish population (𝑁 = 86) indicated thatmutations inCDH1
did not contribute to familial diffuse gastric cancer in Poland
[90]. In this study, the entire coding sequence of CDH1 gene
and exon/intron splice sites were applied for sequencing, but
no pathogenic mutations were detected. This case suggested
the need for mutation screening of other tumor suppressor
genes, such asTP53, or screening for other genetic alterations,
such as deletion, in familial diffuse gastric cancer lacking
CDH1 germline mutations [51].
On the other hand, attention should be paid for the
promoting role of E-cadherin in tumor progression of several
epithelial cancers proposed by recent studies. These include
increased E-cadherin expression for supporting intravasation
and tumor cell survival in inflammatory breast cancer [91,
92], E-cadherin associated mesenchymal to epithelial transi-
tion (MET) and activation of the Akt and MAPK signaling
pathways in ovarian carcinoma [93, 94], and E-cadherin
promoting cell proliferation and migration in a subset of
highly aggressive glioblastoma [95, 96].This process involved
E-cadherin overexpression together with the E-cadherin
associated specific signaling networks in the cytoplasm and
nucleus [97]. This evidence indicates that the presence of E-
cadherin as a tumor suppressor or oncoprotein depends on
the specific cell context.
In summary, E-cadherin and its associated signaling
pathways play important roles in maintaining functions of
gastric mucosa. In contrast, dysregulation of these factors
contributes to gastric cancer initiation and progression.
Detection of the expression and aberrant alterations of E-
cadherin are promising for clinical applications for diagnosis,
prognosis and therapy for gastric cancer. However, it should
be aware of the tumor promoting role of E-cadherin in
specific cell context in order not to render development of
other tumors by reactivation of E-cadherin for therapy of
gastric cancer. Further studies of the functions of E-cadherin
and the mechanisms of its tumor suppressing and tumor
promoting roles are still in need for its wide application in
clinic.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and
D. Forman, “Global cancer statistics,” CA Cancer Journal for
Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] C. D. Mathers and D. Loncar, “Projections of global mortality
and burden of disease from 2002 to 2030,” PLoS Medicine, vol.
3, article e442, no. 11, 2006.
[3] J. Fle´jou, “WHO Classification of digestive tumors: the fourth
edition,” Annales de pathologie, vol. 31, no. 5, pp. S27–S31, 2011.
[4] C. Figueiredo, J. C. Machado, P. Pharoah et al., “Helicobacter
pylori and interleukin 1 genotyping: an opportunity to identify
high-risk individuals for gastric carcinoma,” Journal of the
National Cancer Institute, vol. 94, no. 22, pp. 1680–1687, 2002.
[5] B. Peleteiro, C. Lopes, C. Figueiredo, and N. Lunet, “Salt
intake and gastric cancer risk according to Helicobacter pylori
infection, smoking, tumour site and histological type,” British
Journal of Cancer, vol. 104, no. 1, pp. 198–207, 2011.
[6] J. Paredes, J. Figueiredo, A. Albergaria et al., “Epithelial E- and
P-cadherins: role and clinical significance in cancer,”Biochimica
et Biophysica Acta—Reviews on Cancer, vol. 1826, no. 2, pp. 297–
311, 2012.
[7] C. Caldas, F. Carneiro, H. T. Lynch et al., “Familial gastric
cancer: overview and guidelines for management,” Journal of
Medical Genetics, vol. 36, no. 12, pp. 873–880, 1999.
[8] R. C. Fitzgerald, R. Hardwick, D. Huntsman et al., “Hereditary
diffuse gastric cancer: updated consensus guidelines for clinical
management and directions for future research,” Journal of
Medical Genetics, vol. 47, no. 7, pp. 436–444, 2010.
[9] M. J. G. Bussemakers, A. Van Bokhoven, M. Voller, F. P. Smit,
and J. A. Schalken, “The genes for the calcium-dependent cell
adhesion molecules P- and E-cadherin are tandemly arranged
in the human genome,” Biochemical and Biophysical Research
Communications, vol. 203, no. 2, pp. 1291–1294, 1994.
[10] F. van Roy and G. Berx, “The cell-cell adhesion molecule E-
cadherin,” Cellular and Molecular Life Sciences, vol. 65, no. 23,
pp. 3756–3788, 2008.
[11] M. P. Stemmler, “Cadherins in development and cancer,”Molec-
ular BioSystems, vol. 4, no. 8, pp. 835–850, 2008.
[12] M. Barber, A. Murrell, Y. Ito et al., “Mechanisms and sequelae
of E-cadherin silencing in hereditary diffuse gastric cancer,”
Journal of Pathology, vol. 216, no. 3, pp. 295–306, 2008.
[13] C. Oliveira, S. Sousa, H. Pinheiro et al., “Quantification of
epigenetic and genetic 2nd hits in CDH1 during hereditary
diffuse gastric cancer syndrome progression,”Gastroenterology,
vol. 136, no. 7, pp. 2137–2148, 2009.
[14] S. Valastyan and R. A.Weinberg, “Tumormetastasis: molecular
insights and evolving paradigms,” Cell, vol. 147, no. 2, pp. 275–
292, 2011.
[15] K. Vleminckx, L. Vakaet Jr., M.Mareel,W. Fiers, and F. Van Roy,
“Genetic manipulation of E-cadherin expression by epithelial
tumor cells reveals an invasion suppressor role,” Cell, vol. 66,
no. 1, pp. 107–119, 1991.
[16] T. M. H. Gall and A. E. Frampton, “Gene of the month: E-
cadherin (CDH1),” Journal of Clinical Pathology, vol. 66, pp.
928–932, 2013.
BioMed Research International 7
[17] M. Takeichi, “Morphogenetic roles of classic cadherins,” Cur-
rent Opinion in Cell Biology, vol. 7, no. 5, pp. 619–627, 1995.
[18] B. M. Gumbiner and P. D. McCrea, “Catenins as mediators of
the cytoplasmic functions of cadherins,” Journal of Cell Science,
Supplement, vol. 106, no. 17, pp. 155–158, 1993.
[19] T. Yagi and M. Takeichi, “Cadherin superfamily genes: func-
tions, genomic organization, and neurologic diversity,” Genes
and Development, vol. 14, no. 10, pp. 1169–1180, 2000.
[20] M. Ozawa, M. Ringwald, and R. Kemler, “Uvomorulin-catenin
complex formation is regulated by a specific domain in the
cytoplasmic region of the cell adhesion molecule,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 87, no. 11, pp. 4246–4250, 1990.
[21] R. C. Ireton, M. A. Davis, J. van Hengel et al., “A novel role for
p120 catenin in E-cadherin function,” Journal of Cell Biology,
vol. 159, no. 3, pp. 465–476, 2002.
[22] U. Cavallaro and G. Christofori, “Cell adhesion and signalling
by cadherins and Ig-CAMs in cancer,” Nature Reviews Cancer,
vol. 4, no. 2, pp. 118–132, 2004.
[23] C.M. Niessen, D. Leckband, and A. S. Yap, “Tissue organization
by cadherin adhesion molecules: dynamic molecular and cel-
lular mechanisms of morphogenetic regulation,” Physiological
Reviews, vol. 91, no. 2, pp. 691–731, 2011.
[24] A. Garc´ıa de Herreros and J. Baulida, “Cooperation, ampli-
fication, and feed-back in epithelial-mesenchymal transition,”
Biochimica et Biophysica Acta: Reviews on Cancer, vol. 1825, no.
2, pp. 223–228, 2012.
[25] M. Katoh, “Epithelial-mesenchymal transition in gastric cancer
(Review),” International Journal of Oncology, vol. 27, no. 6, pp.
1677–1683, 2005.
[26] F. J. T. Staal, T. C. Luis, and M. M. Tiemessen, “WNT signalling
in the immune system: WNT is spreading its wings,” Nature
Reviews Immunology, vol. 8, no. 8, pp. 581–593, 2008.
[27] R. T. Moon, A. D. Kohn, G. V. de Ferrari, and A. Kaykas,
“WNT and 𝛽-catenin signalling: diseases and therapies,”Nature
Reviews Genetics, vol. 5, no. 9, pp. 691–701, 2004.
[28] C. J. Gottardi, E. Wong, and B. M. Gumbiner, “E-cadherin
suppresses cellular transformation by inhibiting 𝛽-catenin sig-
naling in an adhesion-independent manner,” Journal of Cell
Biology, vol. 153, no. 5, pp. 1049–1060, 2001.
[29] E. Sahai andC. J.Marshall, “RHO -GTPases and cancer,”Nature
Reviews Cancer, vol. 2, no. 2, pp. 133–142, 2002.
[30] Y. Pan, F. Bi, N. Liu et al., “Expression of seven main Rho family
members in gastric carcinoma,” Biochemical and Biophysical
Research Communications, vol. 315, no. 3, pp. 686–691, 2004.
[31] S. J. Heasman and A. J. Ridley, “Mammalian Rho GTPases:
new insights into their functions from in vivo studies,” Nature
Reviews Molecular Cell Biology, vol. 9, no. 9, pp. 690–701, 2008.
[32] G. Suriano, M. J. Oliveira, D. Huntsman et al., “E-cadherin
germline missense mutations and cell phenotype: evidence for
the independence of cell invasion on the motile capabilities of
the cells,” Human Molecular Genetics, vol. 12, no. 22, pp. 3007–
3016, 2003.
[33] A. Bremm, A. Walch, M. Fuchs et al., “Enhanced activation of
epidermal growth factor receptor caused by tumor-derived E-
cadherin mutations,” Cancer Research, vol. 68, no. 3, pp. 707–
714, 2008.
[34] A. R. Mateus, R. Seruca, J. C. Machado et al., “EGFR regulates
RhoA-GTP dependent cell motility in E-cadherinmutant cells,”
Human Molecular Genetics, vol. 16, no. 13, pp. 1639–1647, 2007.
[35] E. Soto,M. Yanagisawa, L. A.Marlow, J. A. Copland, E. A. Perez,
and P. Z. Anastasiadis, “p120 catenin induces opposing effects
on tumor cell growth depending on E-cadherin expression,”
Journal of Cell Biology, vol. 183, no. 4, pp. 737–749, 2008.
[36] C. F. Cowell, I. K. Yan, T. Eiseler, A. C. Leightner, H. Do¨ppler,
and P. Storz, “Loss of cell-cell contacts inducesNF-𝜅B via RhoA-
mediated activation of protein kinase D1,” Journal of Cellular
Biochemistry, vol. 106, no. 4, pp. 714–728, 2009.
[37] M. Karin and F. R. Greten, “NF-𝜅B: linking inflammation
and immunity to cancer development and progression,” Nature
Reviews Immunology, vol. 5, no. 10, pp. 749–759, 2005.
[38] Y. Ben-Neriah andM. Karin, “Inflammation meets cancer, with
NF-𝜅B as the matchmaker,” Nature Immunology, vol. 12, no. 8,
pp. 715–723, 2011.
[39] S. Kuphal, I. Poser, C. Jobin, C. Hellerbrand, and A. K.
Bosserhoff, “Loss of E-cadherin leads to upregulation of NF𝜅B
activity in malignant melanoma,” Oncogene, vol. 23, no. 52, pp.
8509–8519, 2004.
[40] G. Solanas, M. Porta-de-la-Riva, C. Agusti et al., “E-cadherin
controls 𝛽-catenin and NF-𝜅B transcriptional activity in mes-
enchymal gene expression,” Journal of Cell Science, vol. 121, no.
13, pp. 2224–2234, 2008.
[41] E. van Aken, O. de Wever, C. A. da Rocha, and M. Mareel,
“Defective E-cadherin/catenin complexes in human cancer,”
Virchows Archiv, vol. 439, no. 6, pp. 725–751, 2001.
[42] G. Berx and F. van Roy, “Involvement of members of the cad-
herin superfamily in cancer,” Cold Spring Harbor Perspectives in
Biology, vol. 1, no. 6, Article ID a003129, 2009.
[43] K. Becker, M. J. Atkinson, U. Reich et al., “E-cadherin gene
mutations provide clues to diffuse type gastric carcinomas,”
Cancer Research, vol. 54, no. 14, pp. 3845–3852, 1994.
[44] K. F. Becker and H. Hofler, “Frequent somatic allelic inactiva-
tion of the E-cadherin gene in gastric carcinomas,” Journal of
the National Cancer Institute, vol. 87, no. 14, pp. 1082–1084, 1995.
[45] J. A. Efstathiou, D. Liu, J. M. D. Wheeler et al., “Mutated
epithelial cadherin is associated with increased tumorigenicity
and loss of adhesion and of responsiveness to the motogenic
trefoil factor 2 in colon carcinoma cells,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 96, no. 5, pp. 2316–2321, 1999.
[46] C. Huiping, J. R. Sigurgeirsdottir, J. G. Jonasson et al., “Chro-
mosome alterations and E-cadherin gene mutations in human
lobular breast cancer,”British Journal of Cancer, vol. 81, no. 7, pp.
1103–1110, 1999.
[47] G. Berx, A. Cleton-Jansen, K. Strumane et al., “E-cadherin
is inactivated in a majority of invasive human lobular breast
cancers by truncation mutations throughout its extracellular
domain,” Oncogene, vol. 13, no. 9, pp. 1919–1925, 1996.
[48] J. I. Risinger, A. Berchuck, M. F. Kohler, and J. Boyd, “Mutations
of the E-cadherin gene in human gynecologic cancers,” Nature
Genetics, vol. 7, no. 1, pp. 98–102, 1994.
[49] F. Carneiro, C. Oliveira, G. Suriano, and R. Seruca, “Molecular
pathology of familial gastric cancer, with an emphasis on
hereditary diffuse gastric cancer,” Journal of Clinical Pathology,
vol. 61, no. 1, pp. 25–30, 2008.
[50] P. Guilford, J. Hopkins, J. Harraway et al., “E-cadherin germline
mutations in familial gastric cancer,” Nature, vol. 392, no. 6674,
pp. 402–405, 1998.
[51] C. Oliveira, P. Ferreira, S. Nabais et al., “E-Cadherin (CDH1)
and p53 rather than SMAD4 and Caspase-10 germline muta-
tions contribute to genetic predisposition in Portuguese gastric
8 BioMed Research International
cancer patients,” European Journal of Cancer, vol. 40, no. 12, pp.
1897–1903, 2004.
[52] Y. Zhang, X. Liu, Y. Fan et al., “Germline mutations and
polymorphic variants in MMR, E-cadherin and MYH genes
associated with familial gastric cancer in Jiangsu of China,”
International Journal of Cancer, vol. 119, no. 11, pp. 2592–2596,
2006.
[53] S. Nasri, H. More, F. Graziano et al., “A novel diffuse gastric
cancer susceptibility variant in E-cadherin (CDH1) intron 2: a
case control study in an Italian population,” BMC Cancer, vol.
8, article 138, 2008.
[54] S. Kim, J.W. Chung, T. D. Jeong et al., “Searching for E-cadherin
gene mutations in early onset diffuse gastric cancer and heredi-
tary diffuse gastric cancer in Korean patients,” Familial Cancer,
vol. 12, no. 3, pp. 503–507, 2013.
[55] G. Strathdee, “Epigenetic versus genetic alterations in the
inactivation of E-cadherin,” Seminars in Cancer Biology, vol. 12,
no. 5, pp. 373–379, 2002.
[56] E. Yamamoto, H. Suzuki, H. Takamaru, H. Yamamoto, M.
Toyota, and Y. Shinomura, “Role of DNA methylation in the
development of diffuse-type gastric cancer,” Digestion, vol. 83,
no. 4, pp. 241–249, 2011.
[57] N. R. Salama, M. L. Hartung, and A. Mu¨ller, “Life in the
human stomach: persistence strategies of the bacterial pathogen
Helicobacter pylori,”Nature ReviewsMicrobiology, vol. 11, no. 6,
pp. 385–399, 2013.
[58] D. B. Polk andR.M. Peek Jr., “Helicobacter pylori: gastric cancer
and beyond,”Nature Reviews Cancer, vol. 10, no. 6, pp. 403–414,
2010.
[59] F. Perri, R. Cotugno, A. Piepoli et al., “Aberrant DNA methy-
lation in non-neoplastic gastric mucosa of H. pylori infected
patients and effect of eradication,” The American Journal of
Gastroenterology, vol. 102, no. 7, pp. 1361–1371, 2007.
[60] A. O. O. Chan, J. Z. Peng, S. K. Lam et al., “Eradication
of Helicobacter pylori infection reverses E-cadherin promoter
hypermethylation,” Gut, vol. 55, no. 4, pp. 463–468, 2006.
[61] A. O. Chan, B. C. Wong, H. Lan et al., “Deregulation of E-
cadherin-catenin complex in precancerous lesions of gastric
adenocarcinoma,” Journal of Gastroenterology and Hepatology,
vol. 18, no. 5, pp. 534–539, 2003.
[62] A. O. Chan, S. Lam, B. C.Wong et al., “Promoter methylation of
E-cadherin gene in gastricmucosa associated withHelicobacter
pylori infection and in gastric cancer,” Gut, vol. 52, no. 4, pp.
502–506, 2003.
[63] J. M. David and A. K. Rajasekaran, “Dishonorable discharge:
the oncogenic roles of cleaved E-cadherin fragments,” Cancer
Research, vol. 72, no. 12, pp. 2917–2923, 2012.
[64] M. M. Grabowska and M. L. Day, “Soluble E-cadherin: More
than a symptom of disease,” Frontiers in Bioscience, vol. 17, no.
5, pp. 1948–1964, 2012.
[65] M. Katayama, S. Hirai, K. Kamihagi, K. Nakagawa, M.
Yasumoto, and I. Kato, “Soluble E-cadherin fragments increased
in circulation of cancer patients,” British Journal of Cancer, vol.
69, no. 3, pp. 580–585, 1994.
[66] J. Gofuku, H. Shiozaki, Y. Doki et al., “Characterization of sol-
uble E-cadherin as a disease marker in gastric cancer patients,”
British Journal of Cancer, vol. 78, no. 8, pp. 1095–1101, 1998.
[67] O. deWever, L. Derycke, A. Hendrix et al., “Soluble cadherins as
cancer biomarkers,” Clinical and Experimental Metastasis, vol.
24, no. 8, pp. 685–697, 2007.
[68] A. O. Chan, S. K. Lam, K.M. Chu et al., “Soluble E-cadherin is a
valid prognostic marker in gastric carcinoma,” Gut, vol. 48, no.
6, pp. 808–811, 2001.
[69] A. O. Chan, K. M. Chu, S. K. Lam et al., “Soluble E-cadherin is
an independent pretherapeutic factor for long-term survival in
gastric cancer,” Journal of Clinical Oncology, vol. 21, no. 12, pp.
2288–2293, 2003.
[70] A. O. O. Chan, K. Chu, S. K. Lam et al., “Early prediction of
tumor recurrence after curative resection of gastric carcinoma
by measuring soluble E-cadherin,” Cancer, vol. 104, no. 4, pp.
740–746, 2005.
[71] P. Guilford, B. Humar, and V. Blair, “Hereditary diffuse gastric
cancer: translation of CDH1 germline mutations into clinical
practice,” Gastric Cancer, vol. 13, no. 1, pp. 1–10, 2010.
[72] K. Miura, W. Fujibuchi, and I. Sasaki, “Alternative pre-mRNA
splicing in digestive tract malignancy,” Cancer Science, vol. 102,
no. 2, pp. 309–316, 2011.
[73] C. Oliveira, J. de Bruin, S. Nabais et al., “Intragenic deletion of
CDH1 as the inactivating mechanism of the wild-type allele in
an HDGC tumour,” Oncogene, vol. 23, no. 12, pp. 2236–2240,
2004.
[74] A. R. Brooks-Wilson, P. Kaurah, G. Suriano et al., “Germline
E-cadherin mutations in hereditary diffuse gastric cancer:
assessment of 42 new families and review of genetic screening
criteria,” Journal of Medical Genetics, vol. 41, no. 7, pp. 508–517,
2004.
[75] B. Mayrbaeurl, G. Keller, W. Schauer et al., “Germline mutation
of the E-cadherin gene in three sibling cases with advanced
gastric cancer: clinical consequences for the other family mem-
bers,” European Journal of Gastroenterology andHepatology, vol.
22, no. 3, pp. 306–310, 2010.
[76] F. M. Richards, S. A. McKee, M. H. Rajpar et al., “Germline E-
cadherin gene (CDH1) mutations predispose to familial gastric
cancer and colorectal cancer,” Human Molecular Genetics, vol.
8, no. 4, pp. 607–610, 1999.
[77] T. P. McVeigh, J. K. Choi, N. M. Miller, A. J. Green, and M. J.
Kerin, “ Lobular breast cancer in a CDH1 splice site mutation
carrier: case report and review of the literature,” Clinical Breast
Cancer, vol. 14, no. 2, pp. e47–e51, 2014.
[78] R. Kanasty, J. R. Dorkin, A. Vegas, and D. Anderson, “Delivery
materials for siRNA therapeutics,” Nature Materials, vol. 12, pp.
967–977, 2013.
[79] T. Mart´ınez, N. Wright, M. Lo´pez-Fraga, A. I. Jime´nez,
and C. Pan˜eda, “Silencing human genetic diseases with
oligonucleotide-based therapies,” Human Genetics, vol. 132, no.
5, pp. 481–493, 2013.
[80] T. Tahara, T. Shibata, M. Nakamura et al., “Chronic aspirin
use suppresses CDH1 methylation in human gastric mucosa,”
Digestive Diseases and Sciences, vol. 55, no. 1, pp. 54–59, 2010.
[81] T. Tahara, T. Shibata, H. Yamashita et al., “Chronic nonsteroidal
anti-inflammatory drug (NSAID) use suppresses multiple CpG
islands hyper methylation (CIHM) of tumor suppressor genes
in the human gastric mucosa,”Cancer Science, vol. 100, no. 7, pp.
1192–1197, 2009.
[82] J. K. Christman, “5-Azacytidine and 5-aza-2󸀠-deoxycytidine as
inhibitors of DNA methylation: mechanistic studies and their
implications for cancer therapy,” Oncogene, vol. 21, no. 35, pp.
5483–5495, 2002.
[83] R. L. Momparler, “Epigenetic therapy of cancer with 5-aza-2󸀠-
deoxycytidine (decitabine),” Seminars in Oncology, vol. 32, no.
5, pp. 443–451, 2005.
BioMed Research International 9
[84] C. Zhao and X. Bu, “Promoter methylation of tumorrelated
genes in gastric carcinogenesis,” Histology and Histopathology,
vol. 27, no. 10, pp. 1271–1282, 2012.
[85] A. J.Murgo, “Innovative approaches to the clinical development
ofDNAmethylation inhibitors as epigenetic remodeling drugs,”
Seminars in Oncology, vol. 32, no. 5, pp. 458–464, 2005.
[86] G. Velikova, R. E. Banks, A. Gearing et al., “Circulating soluble
adhesion molecules E-cadherin, E-selectin, intercellular adhe-
sionmolecule-1 (ICAM-1) and vascular cell adhesionmolecule-
1 (VCAM-1) in patients with gastric cancer,” British Journal of
Cancer, vol. 76, no. 11, pp. 1398–1404, 1997.
[87] M. Juhasz, M. P. A. Ebert, H. U. Schulz et al., “Dual role of
serum soluble E-cadherin as a biological marker of metastatic
development in gastric cancer,” Scandinavian Journal of Gas-
troenterology, vol. 38, no. 8, pp. 850–855, 2003.
[88] E. A. Miles, F. Thies, F. A. Wallace et al., “Influence of age
and dietary fish oil on plasma soluble adhesion molecule
concentrations,”Clinical Science, vol. 100, no. 1, pp. 91–100, 2001.
[89] C. Pedrazzani, S. Caruso, G. Corso et al., “Influence of age
on soluble E-cadherin serum levels prevents its utility as a
disease marker in gastric cancer patients,” Scandinavian Journal
of Gastroenterology, vol. 43, no. 6, pp. 765–766, 2008.
[90] A. Jakubowska, M. Ławniczak, B. Wojnarska et al., “CDH1 gene
mutations do not contribute in hereditary diffuse gastric cancer
in Poland,” Familial Cancer, vol. 9, no. 4, pp. 605–608, 2010.
[91] C. G. Kleer, K. L. Van Golen, T. Braun, and S. D. Merajver, “Per-
sistent E-cadherin expression in inflammatory breast cancer,”
Modern Pathology, vol. 14, no. 5, pp. 458–464, 2001.
[92] M. R. Hoffmeyer, K. M. Wall, and S. F. Dharmawardhane,
“In vitro analysis of the invasive phenotype of SUM 149, an
inflammatory breast cancer cell line,” Cancer Cell International,
vol. 5, article 11, 2005.
[93] N. Auersperg, J. Pan, B. D. Grove et al., “E-cadherin induces
mesenchymal-to-epithelial transition in human ovarian surface
epithelium,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 96, no. 11, pp. 6249–6254, 1999.
[94] P. Reddy, L. Liu, C. Ren et al., “Formation of E-cadherin-
mediated cell-cell adhesion activates akt and mitogen activated
protein kinase via phosphatidylinositol 3 kinase and ligand-
independent activation of epidermal growth factor receptor in
ovarian cancer cells,” Molecular Endocrinology, vol. 19, no. 10,
pp. 2564–2578, 2005.
[95] F. J. Rodriguez, B.W. Scheithauer, C. Giannini, S. C. Bryant, and
R. B. Jenkins, “Epithelial and pseudoepithelial differentiation in
glioblastoma and gliosarcoma: a comparative morphologic and
molecular genetic study,” Cancer, vol. 113, no. 10, pp. 2779–2789,
2008.
[96] L. J. Lewis-Tuffin, F. Rodriguez, C. Giannini et al., “Misregulated
E-cadherin expression associated with an aggressive brain
tumor phenotype,” PLoS ONE, vol. 5, no. 10, Article ID e13665,
2010.
[97] F. J. Rodriguez, L. J. Lewis-Tuffin, and P. Z. Anastasiadis,
“E-cadherin’s dark side: possible role in tumor progression,”
Biochimica et Biophysica Acta: Reviews on Cancer, vol. 1826, no.
1, pp. 23–31, 2012.










Hindawi Publishing Corporation 
http://www.hindawi.com













Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
